Daniels A M, McPherson J M, Daniels J R, Piez K A
Target Therapeutics, San Jose, CA 95134.
Biotherapy. 1989;1(3):133-7. doi: 10.1007/BF02170882.
Transforming growth factors beta 1 and beta 2 (TGF-beta 1 and beta 2), tested in a clonogenic assay against primary cells from human tumors, suppress proliferation to different extents. In nineteen of twenty-six cell cultures, proliferation was less than 50% of control with factor at 0.04 or 0.4 nM. Of these, TGF-beta 2 was more active than TGF-beta 1 in fourteen; and TGF-beta 1 was more active than TGF-beta 2 in five. In seven of the nineteen, proliferation was 0% with one or the other factor. In contrast, cisplatin was much less effective in inhibiting proliferation of some of the same cells even at 1,000 or more times the molar concentration of the factors. Surprisingly, when TGF-beta 1 and TGF-beta 2 were combined at equal concentrations, the antiproliferative effect of one was cancelled or markedly inhibited by the other.
在针对人类肿瘤原代细胞的克隆形成试验中检测的转化生长因子β1和β2(TGF-β1和β2),对细胞增殖的抑制程度不同。在26种细胞培养物中的19种中,当因子浓度为0.04或0.4 nM时,增殖率低于对照的50%。其中,在14种培养物中TGF-β2比TGF-β1更具活性;在5种培养物中TGF-β1比TGF-β2更具活性。在这19种培养物中的7种中,使用其中一种或另一种因子时增殖率为0%。相比之下,即使顺铂的摩尔浓度是这些因子的1000倍或更高,其对一些相同细胞增殖的抑制效果也要差得多。令人惊讶的是,当TGF-β1和TGF-β2以相等浓度组合时,其中一种的抗增殖作用会被另一种抵消或显著抑制。